Listed

Jasper Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 16:04 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-07-01 to 2021-09-30$7.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$16.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$10.1mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$24.8mus-gaap:OperatingIncomeLoss
Net income9 months2021-01-01 to 2021-09-30$21.6mus-gaap:NetIncomeLoss
Operating cash flow9 months2021-01-01 to 2021-09-30−$19.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-09-30$100.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$102.4mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$107.2mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$9.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$28.6mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$78.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-21-058660. Last ingested by Listed: Nov 14, 2026, 21:17 ET. Listed shows no prices and gives no investment advice.